Core Concepts
Biomarker testing in advanced NSCLC leads to better patient outcomes and should be a standard practice.
Stats
78% of patients received optimal therapy, 22% received suboptimal treatment.
53.6% in optimal group had comprehensive genomic profiling tests vs 20.3% in suboptimal group.
Median time to next treatment: 11.2 months (optimal) vs 4.4 months (suboptimal).
Median time to treatment discontinuation: 10.4 months (optimal) vs 1.9 months (suboptimal).
Emergency department visits: 0.76 (optimal) vs 1.27 (suboptimal).
Outpatient visits: 22.9 (optimal) vs 42.7 (suboptimal).
Quotes
"These findings suggest that treatment concordant with [comprehensive genomic profiling] findings is associated with better health outcomes."